Associated Papers
Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.
Tögel L et al.
Cancers, 2023
38136436 (PubMed )
Supplement: cancers-15-05892-s001.zip › Supplementary_Tables.xlsx › Table_S2
Next-Generation Sequencing Analysis of Mutations in Circulating Tumor DNA from the Plasma of Patients with Head-Neck Cancer Undergoing Chemo-Radiotherapy Using a Pan-Cancer Cell-Free Assay.
Koukourakis MI et al.
Current Oncology (toronto, Ont.), 2023
Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer.
Nicheperovich A et al.
Journal of Personalized Medicine, 2022
The transcriptional landscape of Shh medulloblastoma.
Skowron P et al.
Nature Communications, 2021
33741928 (PubMed )
Supplement: 41467_2021_21883_MOESM5_ESM.xlsx › _B__Functional_Mutations
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A et al.
Bmc Cancer, 2018
Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.
Bakshi A et al.
Molecular Carcinogenesis, 2017
A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors.
Zhao X et al.
Cancer Discovery, 2017
28923910 (PubMed )
Supplement: 21598290cd170281-sup-180587_2_supp_4253409_2vv5jv.xls › resistant
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ et al.
Cancer Cell, 2015
Select a paper to view details